Latest Ratios: P/E Ratio -0.7x · EV/EBITDA N/A · ROE -165.9%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $40M | $36M | $18M | $19M | — | — | — |
| Enterprise Value | $34M | $29M | $15M | $15M | — | — | — |
| P/E Ratio → | -0.71 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 2.18 | 3.44 | 8.00 | 4.46 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -165.9% | -165.9% | -238.9% | -634.3% | -847.8% | -198.5% | — |
| ROA | -149.0% | -149.0% | -199.9% | -413.9% | -335.0% | -128.9% | -303.9% |
| ROIC | -461.4% | -461.4% | — | — | — | — | — |
| ROCE | -166.7% | -166.7% | -243.9% | -441.5% | -805.8% | -196.2% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.00 | — | 0.13 | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.61 | -1.29 | -1.05 | — | -1.11 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -48.40 | -2.47 | -687.60 | -88.30 | -185.79 |
Net cash position: cash ($6M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 15.75 | 15.75 | 3.99 | 8.70 | 0.36 | 2.66 | 0.04 |
| Quick Ratio | 15.75 | 15.75 | 3.99 | 8.70 | 0.36 | 2.66 | 0.04 |
| Cash Ratio | 9.04 | 9.04 | 3.92 | 8.25 | 0.26 | 2.57 | 0.04 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $24M | $15M | $19M | $15M | $15M | $15M |
Binary clinical trial failure
Based on reported figures, MIRA's price-to-book ratio of 2.30 reflects a market valuation that appears disconnected from the company's underlying asset base, suggesting investors are pricing in the potential for future clinical success rather than current tangible value or historical financial performance metrics.
The current P/B multiple indicates that the market assigns a premium to the company's intellectual property and pipeline potential, despite the lack of revenue or positive earnings. This valuation level warrants caution, as it implies a high degree of optimism regarding MIRA1a's regulatory path that may not be supported by the company's limited cash runway.
As reported in financial statements, MIRA's ROIC has deteriorated to -19.3% in 2026Q1, illustrating the significant capital destruction inherent in funding early-stage CNS research without the benefit of commercialized products to offset the high costs of clinical trial execution and administrative overhead.
The negative trend in return on invested capital suggests that the company is currently unable to generate value from its capital base, which is typical for pre-revenue biotech firms. Investors should monitor whether future clinical milestones can reverse this trend or if the current trajectory of capital consumption will necessitate further dilutive financing.
According to recent SEC filings, MIRA's current ratio has experienced extreme volatility, dropping from 90.53 in 2025Q3 to 82.16 in 2026Q1, which highlights the company's reliance on a shrinking cash position to meet its ongoing operational obligations in the absence of any revenue.
While the current ratio appears high, it is largely a function of the company's limited liabilities rather than operational strength. The rapid decline in cash reserves suggests that the firm's liquidity position is becoming increasingly vulnerable, potentially limiting its ability to navigate unforeseen regulatory or clinical delays.
As indicated by the company's pre-revenue status, the P/E ratio of -0.75 is a fundamentally misapplied metric that obscures the firm's true operational health by focusing on accounting losses rather than the critical cash burn rate required to sustain clinical development activities.
Investors should prioritize cash-based metrics, such as the quarterly burn rate and remaining cash runway, over traditional earnings-based multiples. Using P/E to evaluate MIRA is misleading, as it fails to account for the non-cash nature of stock-based compensation and the binary nature of the company's future value proposition.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MIRA stock.
MIRA Pharmaceuticals, Inc.'s current P/E ratio is -0.7x. This places it at the 50th percentile of its historical range.
MIRA Pharmaceuticals, Inc.'s return on equity (ROE) is -165.9%. The historical average is -201.1%.
Based on historical data, MIRA Pharmaceuticals, Inc. is trading at a P/E of -0.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.